Charles Schwab’s Soleno Therapeutics SLNO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-405,910
| Closed | -$13.6M | – | 3544 |
|
|
2026
Q1 | $13.6M | Buy |
405,910
+4,724
| +1% | +$185K | ﹤0.01% | 1952 |
|
|
2025
Q4 | $18.6M | Buy |
401,186
+11,830
| +3% | +$649K | ﹤0.01% | 1795 |
|
|
2025
Q3 | $26.3M | Buy |
389,356
+93,094
| +31% | +$6.9M | ﹤0.01% | 1569 |
|
|
2025
Q2 | $24.8M | Buy |
296,262
+82,278
| +38% | +$6.16M | ﹤0.01% | 1550 |
|
|
2025
Q1 | $15.3M | Sell |
213,984
-3,566
| -2% | -$174K | ﹤0.01% | 1760 |
|
|
2024
Q4 | $9.78M | Buy |
217,550
+24,953
| +13% | +$1.29M | ﹤0.01% | 2022 |
|
|
2024
Q3 | $9.72M | Buy |
192,597
+130,080
| +208% | +$6.23M | ﹤0.01% | 2035 |
|
|
2024
Q2 | $2.55M | Buy |
62,517
+55,322
| +769% | +$2.34M | ﹤0.01% | 2617 |
|
|
2024
Q1 | $308K | Hold |
7,195
| – | – | ﹤0.01% | 3170 |
|
|
2023
Q4 | $290K | Buy |
+7,195
| New | +$205K | ﹤0.01% | 3227 |
|
|
2021
Q2 | – | Sell |
-8,233
| Closed | -$156K | – | 3529 |
|
|
2021
Q1 | $156K | Sell |
8,233
-2,296
| -22% | -$74K | ﹤0.01% | 3346 |
|
|
2020
Q4 | $305K | Hold |
10,529
| – | – | ﹤0.01% | 3156 |
|
|
2020
Q3 | $397K | Buy |
10,529
+5,725
| +119% | +$167K | ﹤0.01% | 2947 |
|
|
2020
Q2 | $160K | Buy |
+4,804
| New | +$208K | ﹤0.01% | 3197 |
|
Charles Schwab's SLNO Position: Q2 2026 in Review
Charles Schwab sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 405,910 shares — an estimated $13.6M sold.
Charles Schwab first reported a position in SLNO in Q2 2020 and held it in 14 quarters. The position peaked at $26.3M in Q3 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.
- Charles Schwab reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
- Charles Schwab sold 405,910 Soleno Therapeutics shares in Q2 2026, an estimated $13.6M.
- Charles Schwab first reported a position in Soleno Therapeutics in Q2 2020 and held it in 14 quarters.
- Charles Schwab's Soleno Therapeutics position peaked at $26.3M in Q3 2025.
- 0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.
Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.